PH12022552764A1 - Methods of treating agitation associated with alzheimer`s disease - Google Patents
Methods of treating agitation associated with alzheimer`s diseaseInfo
- Publication number
- PH12022552764A1 PH12022552764A1 PH1/2022/552764A PH12022552764A PH12022552764A1 PH 12022552764 A1 PH12022552764 A1 PH 12022552764A1 PH 12022552764 A PH12022552764 A PH 12022552764A PH 12022552764 A1 PH12022552764 A1 PH 12022552764A1
- Authority
- PH
- Philippines
- Prior art keywords
- alzheimer
- disease
- methods
- subject
- agitation associated
- Prior art date
Links
- 238000013019 agitation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 abstract 1
- MKXZASYAUGDDCJ-QNNIAVNKSA-N deudextromethorphan Chemical compound C([C@@H]12)CCC[C@]11CCN(C([2H])([2H])[2H])[C@H]2CC2=CC=C(OC([2H])([2H])[2H])C=C21 MKXZASYAUGDDCJ-QNNIAVNKSA-N 0.000 abstract 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 abstract 1
- 229960004482 quinidine sulfate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016270P | 2020-04-27 | 2020-04-27 | |
| PCT/US2021/029246 WO2021222145A1 (en) | 2020-04-27 | 2021-04-26 | Methomethods of treating agitation associated with alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022552764A1 true PH12022552764A1 (en) | 2024-03-25 |
Family
ID=75914613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/552764A PH12022552764A1 (en) | 2020-04-27 | 2021-04-26 | Methods of treating agitation associated with alzheimer`s disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230270738A1 (enExample) |
| EP (1) | EP4142729A1 (enExample) |
| JP (1) | JP2023523373A (enExample) |
| KR (1) | KR20230016636A (enExample) |
| CN (1) | CN115734787A (enExample) |
| AU (1) | AU2021263354A1 (enExample) |
| BR (1) | BR112022021535A2 (enExample) |
| CA (1) | CA3176234A1 (enExample) |
| IL (1) | IL296977A (enExample) |
| MX (1) | MX2022013427A (enExample) |
| PH (1) | PH12022552764A1 (enExample) |
| TW (1) | TW202203922A (enExample) |
| WO (1) | WO2021222145A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2792662T3 (da) | 2007-05-01 | 2016-07-25 | Concert Pharmaceuticals Inc | Morphinanforbindelser |
| CN115322150B (zh) * | 2021-05-11 | 2024-05-28 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途 |
| KR20240110812A (ko) * | 2021-10-27 | 2024-07-16 | 아바니르 파마슈티컬스, 인코포레이티드 | 알츠하이머병과 관련된 불안을 치료하는 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| US20160143901A1 (en) * | 2006-02-03 | 2016-05-26 | Avanir Pharmaceuticals, Inc. | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia |
| MX370608B (es) | 2007-05-01 | 2019-12-18 | Concert Pharmaceuticals Inc | Compuestos de morfinano. |
| TWI869633B (zh) * | 2014-09-14 | 2025-01-11 | 美商阿瓦尼爾製藥股份有限公司 | 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物 |
-
2021
- 2021-04-26 WO PCT/US2021/029246 patent/WO2021222145A1/en not_active Ceased
- 2021-04-26 EP EP21725652.8A patent/EP4142729A1/en not_active Withdrawn
- 2021-04-26 JP JP2023509465A patent/JP2023523373A/ja active Pending
- 2021-04-26 CA CA3176234A patent/CA3176234A1/en active Pending
- 2021-04-26 CN CN202180045685.XA patent/CN115734787A/zh active Pending
- 2021-04-26 BR BR112022021535A patent/BR112022021535A2/pt not_active IP Right Cessation
- 2021-04-26 PH PH1/2022/552764A patent/PH12022552764A1/en unknown
- 2021-04-26 MX MX2022013427A patent/MX2022013427A/es unknown
- 2021-04-26 AU AU2021263354A patent/AU2021263354A1/en not_active Abandoned
- 2021-04-26 KR KR1020227041229A patent/KR20230016636A/ko active Pending
- 2021-04-26 US US17/921,579 patent/US20230270738A1/en not_active Abandoned
- 2021-04-26 IL IL296977A patent/IL296977A/en unknown
- 2021-04-27 TW TW110115202A patent/TW202203922A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4142729A1 (en) | 2023-03-08 |
| IL296977A (en) | 2022-12-01 |
| WO2021222145A1 (en) | 2021-11-04 |
| BR112022021535A2 (pt) | 2023-01-24 |
| US20230270738A1 (en) | 2023-08-31 |
| KR20230016636A (ko) | 2023-02-02 |
| TW202203922A (zh) | 2022-02-01 |
| WO2021222145A8 (en) | 2021-12-30 |
| MX2022013427A (es) | 2023-01-19 |
| AU2021263354A1 (en) | 2022-10-27 |
| JP2023523373A (ja) | 2023-06-02 |
| CN115734787A (zh) | 2023-03-03 |
| CA3176234A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021222145A8 (en) | Methods of treating agitation associated with alzheimer's disease | |
| Fu et al. | Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint | |
| Addison | On the keloid of alibert, and on true keloid | |
| PH12021500006A1 (en) | Methods of treatment and prevention of alzheimer's disease | |
| MX2024005154A (es) | Métodos de tratamiento de la agitación asociada a la enfermedad de alzheimer. | |
| JP2023541048A5 (enExample) | ||
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| EA202193178A1 (ru) | Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина | |
| JAFFE et al. | Generalized scleroderma in children: acrosclerotic type | |
| MX2024002567A (es) | Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas. | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| Anwar et al. | Combined botulinum toxin injections and phenol nerve/motor point blocks to manage multifocal spasticity in adults | |
| Levine et al. | The therapeutic value of quinidine in coronary thrombosis complicated by ventricular tachycardia | |
| Š? ÁVA et al. | Salazopyrin in the treatment of scleroderma | |
| Pratiwi | The Implementation of Valsava Manuever on Pain Reduction During IV Cannulation: A literature review | |
| CN1063631C (zh) | 乳酸软膏 | |
| Hamizah et al. | Therapeutic Response to Intravenous Iron Therapy for the treatment of Iron Deficiency Anaemia in pregnancy: a Retrospective study in health clinics in Rompin, Pahang (TRIIT) | |
| RU2810400C1 (ru) | Способ лечения стероидной розацеа по точкам | |
| Bhasker et al. | Comparing Effect of 0.25% Bupivacaine and 0.5% Ropivacaine in Transversus Abdominis Plane Block for Postoperative Analgesia in Lower Abdominal Surgeries | |
| 胡金生 | Acupuncture Treatment of Trigeminal Neuralgia | |
| EA202192740A1 (ru) | Фармацевтический набор и способ лечения воспалительных процессов | |
| Zwölfer et al. | Acupuncture in Gonarthrotic Pain—" Bachmann's Knee Program" | |
| WO2025264860A3 (en) | Methods of treating post-covid airway disease | |
| Tudor | TETANUS RESULTING FROM FOREIGN BODY IN THE NOSE: REPORT OF A CASE | |
| FLEMENBAUM | Amphetamine Hyperactivity in Rats |